TG Therapeutics | TGTX - Operating Expenses

Stock Price
29.11
Daily Change
-0.63 -2.10%
Monthly
-2.66%
Yearly
-12.26%
Q1 Forecast
28.52

TG Therapeutics reported $132.34M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Alaunos Therapeutics USD 1.19M 428K Sep/2025
Amgen USD 5.9B 773M Dec/2025
Ardelyx USD 105.66M 6.4M Sep/2025
Arrowhead Research USD 212.37M 19.05M Sep/2025
Bayer EUR 10.2B 523M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Dynavax Technologies USD 73.6M 7.41M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Novartis USD 9.86B 115M Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 132.34M 26.04M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025